8 completed, 1 not yet recruiting. 4 Phase 3, 2 Early Phase 1, 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 4 |
| Early Phase 1 | 2 | Completed 2 |
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Completed 1, Not yet recruiting 1 |
Follow Adrian Vella: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction Caloric Restriction, Hyperglycemic clamp - Type2diabetes | Phase 2 | Not yet recruiting | Adrian Vella | 20 | 2027-12-15 | 2026-10-28 |
| The Effects of Glucagon on Hepatic Metabolism Glucagon response study - Obesity, Type2diabetes | Phase 1 / Phase 2 | Completed | Adrian Vella | 21 | 2022-10-20 | 2026-10-14 |
| A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics Saline, Exendin-9,39, Liraglutide - Healthy | Phase 3 | Completed | Adrian Vella | 21 | 2022-10-17 | 2026-10-28 |
| Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes Saline, Exendin-9,39, Saline + Intralipid/Heparin - Healthy, Type 2 Diabetes | Phase 3 | Completed | Adrian Vella | 23 | 2021-04-15 | 2023-12-26 |
| A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion Exendin-9,39, Saline - Healthy | Phase 3 | Completed | Adrian Vella | 11 | 2021-03-04 | 2023-06-09 |
| The Effect of the Interaction of Glucagon and Insulin on Endogenous Glucose Production in Humans 0.4mU Insulin followed by withdrawal period followed by 0.8mU study, 0.8mU Insulin followed by withdrawal period followed by 0.4mU study - Healthy | Phase 3 | Completed | Adrian Vella | 12 | 2020-10-14 | 2022-06-21 |
| The Contribution of Incretin Hormones to Post-prandial Glucose Metabolism After Roux-en-Y Gastric Bypass Exendin 9, 39, Placebo - Type 2 Diabetes Mellitus | Early Phase 1 | Completed | Adrian Vella | 20 | 2012-03-01 | 2013-12-04 |
| The Contribution of Incretin Hormones to the Amelioration of Glucose Metabolism After Roux-en-Y Gastric Bypass Exendin 9,39, Placebo - Type 2 Diabetes Mellitus | Early Phase 1 | Completed | Adrian Vella | 12 | 2011-06-01 | 2013-12-04 |
| Dose-response Study of Exendin-9,39 on Glucose Metabolism saline infusion, GLP-1-9,36 infusion, Exendin-9,39 at low dose - Pancreatic Effects of 9,39-Exendin and 9,36-GLP-1 | Phase 1 | Completed | Adrian Vella | 11 | 2011-05-01 | 2013-01-23 |
Diabetes Mellitus, Type 2 (3) · Fatty Liver (2) · Insulin Resistance (2) · Non-alcoholic Fatty Liver Disease (1) · Obesity (1)
Sodium Chloride (3) · Caloric Restriction (1) · Glucagon (1) · Heparin (1) · Liraglutide (1) · exendin (9-39) (1) · soybean oil, phospholipid emulsion (1)
United States (9)
R01DK126206 (3), R01DK082396 (2), UL1RR024150 (2), R01DK116231 (1)